Onivyde in combination with 5-fluorouracil and leucovorin received marketing authorization from The European Commission

Jonathan Mahler on his front-page story in the NYT Magazine on Trump’s deliberate dismantling of America’s War on Cancer

Readers of The Cancer Letter and listeners of The Cancer Letter Podcast are familiar with the impact of President Donald Trump’s first nine months in office on the field of oncology. Now, the threats posed to oncology are being brought to the attention of a general audience—Jonathan Mahler, staff writer for The New York Times Magazine, wrote an in-depth article about how the Trump administration’s actions have brought chaos, uncertainty, and damage to the oncology research community.

September 17, 2025

Podcast The Directors

The Directors: Ben Ho Park and Suresh Ramalingam discuss tough times, uncertainty, and resilience
“If you’re going to be an oncologist, we look at the glass 5% full, not 95% empty.”

In the face of the unknown, two cancer center leaders discuss planning for the future, recovering from setbacks, and holding on to what they still have.

September 12, 2025

Vol.51 No.33

By Claire Marie Porter, Jacquelyn Cobb and Paul Goldberg

Guest Editorial

Reflections of a cancer scientist
Maintaining the pace of novel technologies will lead to more efficient and less toxic medicines

Look at where our understanding of cancer was two, five, 10, 15, 20, or more years ago and then consider what has happened over the past two decades. We finally realized how more complex the problem of cancer is—more than any of us imagined.

September 12, 2025

Vol.51 No.33

By Ze’ev Ronai

Breaking barriers in lung cancer research

The fight against lung cancer is evolving, with groundbreaking research shedding light on the intricate interplay between biology, environment, and health disparities.

September 12, 2025

Vol.51 No.33

By Loretta Erhunmwunsee

Obituary

Nobel laureate David Baltimore dies at 87
Baltimore discovered that genetic material of tumor viruses could make DNA from their RNA genome

All photos courtesy of CalTechDavid Baltimore, co-recipient of the 1975 Nobel Prize in Physiology or Medicine and president emeritus and the Judge Shirley Hufstedler Professor of Biology at Caltech, died on Sept. 6. He was 87.

September 12, 2025

Vol.51 No.33

By Lori Dajose

Obituary

Harvey Golomb, past chair of UChicago’s Department of Medicine, dies at 82
Golomb was a translational scientist (before that term was in vogue)

It is with profound sadness that I announce the passing of our esteemed colleague and friend, Dr. Harvey Golomb. He died on Aug. 20.

September 12, 2025

Vol.51 No.33

By Everett E. Vokes

Onivyde in combination with 5-fluorouracil and leucovorin received marketing authorization from The European Commission

YOU MAY BE INTERESTED IN

Jonathan Mahler on his front-page story in the NYT Magazine on Trump’s deliberate dismantling of America’s War on Cancer

The Directors: Ben Ho Park and Suresh Ramalingam discuss tough times, uncertainty, and resilience
“If you’re going to be an oncologist, we look at the glass 5% full, not 95% empty.”

Reflections of a cancer scientist
Maintaining the pace of novel technologies will lead to more efficient and less toxic medicines

Breaking barriers in lung cancer research

Nobel laureate David Baltimore dies at 87
Baltimore discovered that genetic material of tumor viruses could make DNA from their RNA genome

Harvey Golomb, past chair of UChicago’s Department of Medicine, dies at 82
Golomb was a translational scientist (before that term was in vogue)

Renew today!

Subscriber content

Never miss an issue!

Login

Onivyde in combination with 5-fluorouracil and leucovorin received marketing authorization from The European Commission

YOU MAY BE INTERESTED IN

Jonathan Mahler on his front-page story in the NYT Magazine on Trump’s deliberate dismantling of America’s War on Cancer

The Directors: Ben Ho Park and Suresh Ramalingam discuss tough times, uncertainty, and resilience“If you’re going to be an oncologist, we look at the glass 5% full, not 95% empty.”

Reflections of a cancer scientistMaintaining the pace of novel technologies will lead to more efficient and less toxic medicines

Breaking barriers in lung cancer research

Nobel laureate David Baltimore dies at 87Baltimore discovered that genetic material of tumor viruses could make DNA from their RNA genome

Harvey Golomb, past chair of UChicago’s Department of Medicine, dies at 82Golomb was a translational scientist (before that term was in vogue)

Never miss an issue!

Login

The Directors: Ben Ho Park and Suresh Ramalingam discuss tough times, uncertainty, and resilience
“If you’re going to be an oncologist, we look at the glass 5% full, not 95% empty.”

Reflections of a cancer scientist
Maintaining the pace of novel technologies will lead to more efficient and less toxic medicines

Nobel laureate David Baltimore dies at 87
Baltimore discovered that genetic material of tumor viruses could make DNA from their RNA genome

Harvey Golomb, past chair of UChicago’s Department of Medicine, dies at 82
Golomb was a translational scientist (before that term was in vogue)